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PERIPHERAL VASCULAR DISEASE
Restoring Vascular Nitric Oxide Formation by L-Arginine Improves
the Symptoms of Intermittent Claudication in Patients With
Peripheral Arterial Occlusive Disease
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Background. Administration of L-arginine improves nitric oxide
(NO) formation and endothelium-dependent vasodilation in ath-
erosclerotic patients.
Objectives. We investigated in this double-blind, controlled
study whether prolonged intermittent infusion therapy with
L-arginine improves the clinical symptoms of patients with inter-
mittent claudication, as compared with the endothelium-
independent vasodilator prostaglandin E1, and control patients.
Methods. Thirty-nine patients with intermittent claudication
were randomly assigned to receive 2 3 8 g L-arginine/day, or 2 3
40 mg prostaglandin E1 (PGE1)/day or no hemodynamically active
treatment, for 3 weeks. The pain-free and absolute walking
distances were assessed on a walking treadmill at 3 km/h, 12%
slope, and NO-mediated, flow-induced vasodilation of the femoral
artery was assessed by ultrasonography at baseline, at 1, 2 and 3
weeks of therapy and 6 weeks after the end of treatment. Urinary
nitrate and cyclic guanosine-3*, 5*-monophosphate (GMP) were
assessed as indices of endogenous NO production.
Results. L-Arginine improved the pain-free walking distance by
230 6 63% and the absolute walking distance by 155 6 48% (each
p < 0.05). Prostaglandin E1 improved both parameters by 209 6
63% and 144 6 28%, respectively (each p < 0.05), whereas control
patients experienced no significant change. L-Arginine therapy
also improved endothelium-dependent vasodilation in the femoral
artery, whereas PGE1 had no such effect. There was a significant
linear correlation between the L-arginine/asymmetric dimethyl-
arginine (ADMA) ratio and the pain-free walking distance at
baseline (r 5 0.359, p < 0.03). L-Arginine treatment elevated the
plasma L-arginine/ADMA ratio and increased urinary nitrate and
cyclic GMP excretion rates, indicating normalized endogenous
NO formation. Prostaglandin E1 therapy had no significant effect
on any of these parameters. Symptom scores assessed on a visual
analog scale increased from 3.51 6 0.18 to 8.3 6 0.4 (L-arginine)
and 7.0 6 0.5 (PGE1; each p < 0.05), but did not significantly
change in the control group (4.3 6 0.4).
Conclusions. Restoring NO formation and endothelium-
dependent vasodilation by L-arginine improves the clinical symp-
toms of intermittent claudication in patients with peripheral
arterial occlusive disease.
(J Am Coll Cardiol 1998;32:1336–44)
©1998 by the American College of Cardiology
Peripheral arterial occlusive disease (PAOD) is a manifesta-
tion of generalized atherosclerosis; many PAOD patients also
suffer from atherosclerotic complications at other sites that are
frequently affected, like the coronary and extracranial carotid
arteries (1). Recent studies on the pathophysiology of athero-
sclerotic vascular disease have shown that the endothelium
plays a crucial role in the active regulation of local blood flow.
Atherosclerosis is characterized by decreased ability of the
endothelium to induce vasodilation (2). This is mainly due to
impaired biological activity of the endothelium-derived vaso-
dilators, nitric oxide (NO) and prostacyclin (3). Prostaglandin
E1 (PGE1) activates prostacyclin receptors and thereby in-
duces endothelium-independent vasodilation; it has been used
for several years in the pharmacologic treatment of patients
with severe PAOD (4,5).
Nitric oxide, which is synthesized from the amino acid
precursor L-arginine, is constitutively released from the endo-
thelium and contributes to the physiologic regulation of blood
pressure and vascular tone (6). The biological activity of NO is
impaired in animal models of hypercholesterolemia (7,8) and
in patients with atherosclerotic vascular disease (9,10). Exper-
imentally, chronic supplementation with L-arginine reduces the
progression of atherosclerosis in cholesterol-fed rabbits
(8,11). In hypercholesterolemic and atherosclerotic humans,
acute intravenous administration of L-arginine improves
endothelium-dependent vasodilation in the coronary (9) and in
the peripheral circulation (12). We have recently shown that a
single intravenous infusion of L-arginine increases the perfu-
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sion of the diseased leg in patients with critical limb ischemia
(13). However, it has not been investigated in these studies
whether the hemodynamic effects of L-arginine are maintained
during an intermittent infusion therapy lasting for several
weeks, and whether improved endothelial function is associ-
ated with improved clinical symptoms of atherosclerotic vas-
cular disease. Therefore, the present study was performed to
investigate whether intermittent intravenous infusion therapy
with L-arginine improves the symptoms of intermittent claudi-
cation in PAOD patients as compared with the endothelium-
independent peripheral vasodilator, PGE1. A third group of
patients was studied who did not receive a peripheral vasodi-
lator (control group) in order to allow for fluctuations in the
natural course of disease activity.
Methods
Patients and study design. Thirty-nine patients with
PAOD (Fontaine stage IIb) were included into this study after
they had given their informed consent. The clinical character-
istics of the patients are given in Table 1. The study protocol
had previously been approved by the local Institutional Review
Board for Studies in Humans; it conformed with recent
national and international guidelines for therapeutic studies in
patients with peripheral arterial disease (14–16). Inclusion
criteria were: the presence of stable intermittent claudication
due to chronic PAOD Fontaine stage IIb, defined as the
presence of stenoses in the arterial vessels of the lower limbs as
confirmed by angiography (within 3 months before inclusion
into the study, n 5 18) or duplex ultrasonography (at the time
of inclusion into the study, n 5 21); symptoms of intermittent
claudication with no rest pain for at least 12 months; and no
major change ($20%) in pain-free walking distance on two
different occasions within 4 weeks before the beginning of the
study. Exclusion criteria were the presence of systemic inflam-
matory, renal or liver diseases, recent progression of PAOD,
indication for peripheral angioplasty or bypass surgery, con-
comitant diseases associated with reduced walking distance
(arthrosis, arthritis, diseases of the spinal column, venous
diseases, cardiopulmonary insufficiency with or without coro-
nary disease, neurologic diseases) or conditions interfering
with a normal conduction of the trial (seriously impaired
Table 1. Baseline Characteristics of the Patients
L-Arginine PGE1 Control
Patients (n) 13 13 13
Sex (M/F) 6/4 9/4 9/4
Age (yr) 70.1 6 2.8 66.1 6 3.6 66.8 6 2.4
(range) 49–87 48–89 53–82
Height (cm) 169.8 6 2.4 168.2 6 2.7 170.2 6 1.9
Weight (kg) 72.7 6 2.6 74.0 6 3.5 77.1 6 4.0
Systolic blood pressure (mm Hg) 153.1 6 6.2 150.4 6 5.6 152.7 6 5.4
Diastolic blood pressure (mm Hg) 78.1 6 2.7 77.7 6 4.2 82.3 6 3.6
Plasma total cholesterol (mmol/L) 5.8 6 0.3 6.2 6 0.4 5.9 6 0.3
Classification of PAOD
Pain-free walking distance (m) 53.0 6 9.0 56.3 6 12.3 53.6 6 4.8
Absolute walking distance (m) 93.7 6 12.9 98.3 6 19.8 99.6 6 9.7
Ankle-arm blood pressure index 0.53 6 0.06 0.55 6 0.04 0.59 6 0.06
Occlusion type
Femoral (n) 8 8 8
Multisegmental (n) 4 5 4
Tibioperoneal (n) 1 0 1
Cardiovascular risk factors (n)
Hypercholesterolemia 8 9 8
Hypertension 8 9 8
History of smoking 7 7 7
Diabetes mellitus 4 (type II) 3 (type II) 3 (type II)
Coronary heart disease 7 7 7
Carotid artery stenosis 6 6 6
Comedication (n)
Acetylsalicylic acid (100 mg/d) 10 10 9
Calcium channel blockers 9 7 5
Lipid-lowering drugs 2 2 2
Nitroglycerine spray 4 4 3
Oral antidiabetics 2 2 1
Insulin 2 1 1
Other (miscellaneous) 5 6 5
Data are given as mean 6 SEM. There were no statistically significant differences between the groups in any of the
parameters. See text for abbreviations.
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cerebral function). All analgesic medication was omitted dur-
ing the entire study period; all other medication was kept
constant during the study. The comedication of the patients is
listed in Table 1.
At the time of inclusion into the study, the pain-free and
total walking distances were assessed on a walking treadmill
(3 km/h, 12% slope). Systemic arterial blood pressure and
systolic ankle pressures in the dorsal foot artery and the
posterior tibial artery were measured before and after the
treadmill test. Blood flow in the femoral artery and femoral
artery diameter were determined by duplex ultrasonography at
baseline and during the hyperemic reaction induced by 3 min
of suprasystolic occlusion using an adequately sized blood
pressure cuff around the thigh. A 24 h urine and a venous
plasma sample were collected for biochemical analyses.
Thereafter, the patients were randomly assigned to one of
three groups. The first group received two intravenous infu-
sions daily of 8 g of L-arginine dissolved in 50 ml of physiologic
saline, for 3 weeks (L-arginine group, n 5 13). The second
group received two intravenous infusions daily of 40 mg of
PGE1 dissolved in 50 ml of physiologic saline, for 3 weeks
(PGE1 group, n 5 13). Patients in these two groups were
additionally asked to maintain a walking training (three times
daily, 15 min of walking up to the onset of claudication pain).
Patients in the third group were outpatients; they were asked
to maintain the same level of walking exercise for 3 weeks as
the first two groups, and did not receive any peripheral
vasodilators throughout the study period (control group, n 5
13). Patients in the first two groups were blinded as to which of
the medications they received, as were the investigators per-
forming the analyses. The walking training was explained to all
patients with the help of a formalized instruction sheet, and the
training was supervised by one of the investigators once a
week. During the entire study period patients were asked to
assess claudication-associated pain every day using a subjective
analog scale graded from 0 (maximal pain even during rest) to
10 (no pain at all during everyday exercise intensity).
After 1, 2 and 3 weeks of treatment and 6 weeks after the
end of the treatment period, the hemodynamic and biochem-
ical measurements were repeated. Plasma samples were always
drawn in the morning before the infusions. All investigators
performing the treadmill tests and the hemodynamic and
biochemical measurements were blinded to treatment assign-
ment.
Hemodynamic measurements. Blood pressure and heart
rate were measured by the standard sphygmomanometric
method after the patients had rested in the supine position for
at least 20 min.
Femoral arterial blood flow velocity and diameter were
measured by image-directed duplex ultrasonography in a seg-
ment of the superficial femoral artery with a longitudinal
cross-section. Measurements were made in the more severely
affected leg using a DF 400 image-directed duplex ultrasound
system (Diasonics-Sonotron, Cologne, Germany) with a trans-
ducer combining 7.5-MHz B-mode imaging and 3-MHz pulsed
Doppler beams, as described previously (13), according to the
procedure described by Sorensen et al. (17). All studies were
performed in a temperature-controlled room (20 to 23°C). The
subjects rested in the supine position for 15 min before the first
scan, and remained supine until the last recording was finished.
The vessel was scanned just below the bifurcation into the
superficial and profound femoral arteries, and the transducer
was adjusted in the position that produced the clearest images
of the anterior and posterior wall of the superficial femoral
artery. Vessel diameter was calculated using the electronic
caliper of the ultrasound system as the mean value of at least
seven repeated measurements. After each determination of
vessel diameter, blood flow volume was automatically calcu-
lated as the product of the cross-sectional area and the
time-averaged blood flow velocity (17,18). Interassay variabil-
ity was previously determined as 3.2% with our system. The
optimal position of the transducer was marked on the skin at
the first investigation using a permanent marker, and the same
position and scanning orientation were relocated at the follow-
ing investigations. Hyperemia was induced by inflating an
adequately sized blood pressure cuff around the thigh to
suprasystolic pressure for 3 min. The scanning position of the
ultrasound transducer was fixed throughout this procedure.
Immediately after releasing pressure, repeated measurements
were performed until blood flow had returned to baseline.
Systolic ankle blood pressures were measured by directional
Doppler sonography before and after a constant load treadmill
test at a velocity of 3 km/h and a slope of 12%. Systemic
arterial blood pressure was measured simultaneously, and the
ankle-arm pressure indices were calculated for each leg. Val-
ues are given for the clinically predominant leg.
Biochemical analyses. Urinary nitrate excretion was
determined as its pentafluorobenzyl derivative by gas
chromatography-mass spectrometry, as described previously
(13,19). The detection limit of the method was 20 fmol/ml.
Intraassay variability was below 3.8%. Cyclic guanosine-39,
59-monophosphate (cGMP) concentrations in urine samples
were measured by radioimmunoassay using [125I]-cGMP as a
tracer after acetylation of the samples, as described previously
(13). The detection limit of the assay was 83 fmol/ml. Urinary
creatinine was determined spectrophotometrically with the
alkaline picric acid method in an automatic analyzer (Beck-
man, Galway, Ireland). The urinary excretion rates of nitrate
and cGMP were corrected by urinary creatinine concentration
in order to reduce the variability due to differences in renal
excretory function (20).
Plasma L-arginine and dimethylarginine concentrations
were determined by high performance liquid chromatography
using precolumn derivatization with o-phthalaldehyde, as de-
scribed previously (21). The variability of the method was
below 5.5%; the detection limit of the assay was 0.1 mmol/L.
Serum total cholesterol and triglyceride concentrations
were measured by standard spectrophotometric methods.
Calculations and statistical analysis. Data are given as
mean 6 SEM. Statistical significance of treatment effects on
pain-free and absolute walking distance and on biochemical
parameters was tested using repeated measurements analysis
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of variance (ANOVA) followed by the Scheffe´ F test. Single
comparisons between the groups were tested for statistical
significance using ANOVA followed by Fisher’s protected
least-significant difference test. Linear regression curves and
correlation coefficients were calculated according to the least
squares method. Statistical significance was accepted for p ,
0.05.
Results
Clinical observations and side effects. Infusion of
L-arginine was generally well tolerated by the patients, except
in one subject who experienced a mild allergic skin reaction of
arms and legs, which was relieved using an oral antihistaminic
without interrupting L-arginine treatment. Prostaglandin E1
infusion caused local pain and skin reddening at the site of the
infusion in four patients, which usually relented within 1 h after
the end of the infusion; treatment was continued in all patients.
In the control group one patient dropped out of the study after
week 2 because he was admitted for angioplasty due to an
acute worsening of the symptoms of PAOD. None of the
patients from the L-arginine or PGE1 groups had to undergo
additional therapy for peripheral vascular disease until at least
6 weeks after the end of the active treatment period.
Walking distances. All patients had similar pain-free and
absolute walking distances at entry into the study (51.7 6 5.1
and 93.2 6 8.0 m, respectively), and all were graded as
Fontaine stage IIb (i.e., absolute walking distance ,200 m).
Administration of L-arginine resulted in a continuous increase
in the pain-free and the absolute walking distances (Fig. 1).
After 3 weeks of treatment, the mean pain-free walking
distance in this group was 147.2 6 33.2 m and the absolute
walking distance was 216.1 6 40.3 m (each p , 0.05 vs.
baseline). A similar therapeutic effect was also induced by
intermittent PGE1 infusions (127.7 6 24.9 and 199.1 6 35.4 m
for the pain-free and absolute walking distances, respectively;
each p , 0.05 vs. baseline). There was no significant difference
between both active treatments. At the end of the infusion
therapy, six patients in the L-arginine group and five patients in
the PGE1 group had absolute walking distances $200m, that
is, they were now graded as Fontaine stage IIa. In the control
group only a slight improvement of the pain-free and the
absolute walking distances was observed (65.8 6 9.0 and
130.4 6 14.6 m, p 5 NS), and only one patient was graded as
Fontaine stage IIa in this group after 3 weeks. Six weeks after
the end of the active treatment period, both the pain-free and
the absolute walking distances showed a slight trend to further
increase in the L-arginine group (to 176.3 6 44.6 and 271.7 6
51.5 m, respectively, n 5 8), with five patients graded as
Fontaine stage IIa at this time point. In contrast, no further
increase of the walking distances was noted in the PGE1 group
(123.6 6 26.1 and 191.4 6 26.8 m, n 5 11; six patients graded
as Fontaine stage IIa) nor in the control group (70.0 6 10.3
and 146.9 6 24.3 m, n 5 8; two patients graded as Fontaine
stage IIa).
Hemodynamic measurements. There was no significant dif-
ference in systemic blood pressures at baseline or during the
treatment between any of the groups. At baseline, mean
hyperemia-induced femoral artery dilation after 3 min of supra-
systolic occlusion was 3.6 6 0.8%. Flow-mediated femoral artery
dilation was progressively increased during intermittent
L-arginine infusion therapy, reaching a maximal flow-mediated
vasodilation of 7.2 6 1.1% and 6.9 6 1.3% at 2 and 3 weeks,
respectively (p , 0.05 vs. baseline in weeks 2 and 3; Fig. 2a). Six
weeks after the end of the active treatment period, flow-mediated
vasodilation was still significantly greater than at baseline in this
group (5.7 6 1.1%). In contrast, PGE1 only slightly enhanced
flow-mediated femoral artery dilation (to 4.0 6 0.7% in week 3,
p 5 NS; Fig. 2b), and in the control group flow-induced dilation
was unchanged (Fig. 2c). These differences in flow-induced
femoral artery dilation could not be accounted for by differences
in basal diameter (L-arginine group, 5.8 6 0.3 mm; PGE1 group,
5.8 6 0.3 mm; control group 5.9 6 0.2 mm). Despite an
Figure 1. Effect of intravenous infusion therapy with L-arginine or
PGE1 on the pain-free (a) and absolute walking distance (b) in patients
with chronic stable intermittent claudication. Data are mean 6 SEM.
*p , 0.05.
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unchanged peak femoral arterial flow, L-arginine treatment sig-
nificantly increased the duration of the hyperemic response, as
assessed by the area under the blood flow time curve (area under
the curve [AUC]), and by the time elapsing between peak
hyperemia and return to 50% of peak flow (t1/2; Fig. 3). In the
PGE1 and control groups, no significant changes in peak flow,
AUC or t1/2 were observed (Fig. 3).
Baseline ankle-arm blood pressure indices were 0.64 6 0.03
at rest; they decreased to 0.38 6 0.02 after treadmill exercise
(mean difference preexercise vs. postexercise, 239.3 6 3.4%).
In the L-arginine group, ankle-arm blood pressure indices at
rest and after exercise increased during treatment; postexercise
values in week 3 were 0.48 6 0.06 and further increased to
0.55 6 0.07 at 6 weeks. In the PGE1 group this reaction was
similar (postexercise ankle-arm blood pressure index in week
3, 0.50 6 0.06), but systolic ankle blood pressures showed no
further increase 6 weeks after the end of the active treatment
period (0.51 6 0.04). No consistent change was observed in the
control group at rest or after exercise.
Pain scale. Self-assessment of the patients on a visual
analog pain scale showed that all patients were suffering from
severe claudication-associated pain during everyday activities
(mean pain rating at baseline, 3.51 6 0.18 on a scale defined as:
maximal pain 5 0 and no pain at all 5 10). Both active
treatments induced a statistically significant increase in the
score, indicating an improvement of claudication-associated
pain. This increase was more pronounced in the L-arginine
group (to 8.3 6 0.4) than in the PGE1 group (to 7.0 6 0.5, p ,
0.05 between both groups). In the control group a small
increase of the score was also observed (to 4.3 6 0.4), which,
however, did not reach statistical significance.
Biochemical analyses. Baseline plasma L-arginine concen-
tration was 90.3 6 6.2 mmol/L with no significant difference
between the groups. Intermittent infusion therapy with
L-arginine resulted in about a twofold increase of plasma
L-arginine concentrations (Table 2). Neither in the PGE1
group nor in the control group were any significant changes in
plasma L-arginine concentrations observed.
The plasma concentrations of asymmetric dimethylarginine
(ADMA) (3.49 6 0.32 mmol/L; age-adjusted normal range,
1.0 6 0.1 mmol/L [10]) and symmetric dimethylarginine
(2.90 6 0.44 mmol/L; age-adjusted normal range, 0.8 6 0.1
mmol/L [10]) were elevated above the normal range at baseline
and remained unchanged during the entire study in all three
groups (Table 2). However, the elevation of L-arginine plasma
concentrations in the L-arginine group resulted in significantly
increased L-arginine/ADMA ratios in this group during weeks
1 to 3 (Table 2). There was a significant linear correlation
between the L-arginine/ADMA ratio and the pain-free walking
distance at baseline (r 5 0.359, p , 0.03); the increase in
L-arginine/ADMA ratio during L-arginine treatment was also
significantly correlated with the increase in pain-free walking
distance in this group (r 5 0.385, p , 0.02).
The urinary excretion rates of nitrate and cGMP were below
the normal range at the beginning of the study (nitrate, 120.3 6
7.4 mmol/mmol creatinine; age-adjusted normal range, 156.0 6
7.8 mmol/mmol creatinine [10]; cGMP, 109.7 6 16.2 nmol/mmol
creatinine; age-adjusted normal range, 150.0 6 8.3 nmol/mmol
creatinine [10]). Infusion therapy with L-arginine increased uri-
nary nitrate and cGMP excretion rates (each p , 0.05 vs. control;
Figure 2. Changes of femoral artery diameter during the hyperemic
reaction induced by 3 min of suprasystolic occlusion before, during and
after 3 weeks of infusion therapy with L-arginine (a), PGE1 (b), or in
control patients (c), as well as 6 weeks after the end of the active
treatment period. Data are mean 6 SEM.
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p , 0.05 for nitrate in L-arginine vs. PGE1 group; Fig. 4). There
was no significant change in urinary nitrate or cGMP excretion
rates in either the PGE1 or in the control group. There was a
significant linear correlation between urinary nitrate and cGMP
excretion rates (r 5 0.472, p , 0.01). Urinary nitrate excretion
rates were significantly correlated with the pain-free (r 5 0.356,
p , 0.01) and absolute walking distances (r 5 0.318, p , 0.01).
Plasma total cholesterol and triglyceride levels and plasma
creatinine concentrations were not statistically significantly
different between either of the groups at any time point.
Discussion
The present study is the first to demonstrate that restora-
tion of vascular NO formation with L-arginine improves the
clinical symptoms of atherosclerotic vascular disease in hu-
mans. An intermittent intravenous infusion therapy with
L-arginine significantly increased the pain-free and absolute
walking distances of patients with chronic stable intermittent
claudication. This effect was associated with a significant
improvement of flow-induced, endothelium-dependent vasodi-
Figure 3. Bar graphs showing peak femoral artery
flow (ml/min), increase in femoral artry diameter
(as percent of baseline diameter) during reactive
hyperemia before and after 3 weeks of intermittent
infusion therapy with L-arginine or PGE1, and in
control patients. The area under the curve (AUC,
arbitrary units) of femoral artery flow during hyper-
emia and the time elapsing between peak hyperemia
and return to 50% of this peak (t1/2, s) are also
shown. Data are mean 6 SEM. *p , 0.05 vs.
baseline. Striped columns 5 baseline; solid col-
umns 5 3 weeks.
Table 2. Plasma L-Arginine and Dimethylarginine Concentrations
Group Baseline 1 Week 2 Weeks 3 Weeks 16 Weeks
L-arginine (mmol/L) L-Arginine 83.2 6 11.6 161.1 6 50.0* 138.1 6 31.2* 163.2 6 35.1* 118.5 6 28.0
PGE1 93.0 6 12.5 83.8 6 11.3 95.0 6 11.7 88.0 6 11.2 83.9 6 7.8
Control 94.8 6 8.3 83.5 6 8.1 88.6 6 9.4 94.5 6 13.2 95.9 6 12.2
ADMA (mmol/L) L-Arginine 3.43 6 0.37 3.61 6 0.78 3.14 6 0.40 3.51 6 0.44 4.54 6 0.94
PGE1 3.60 6 0.66 3.49 6 0.64 5.14 6 1.07 4.32 6 0.84 3.80 6 0.74
Control 3.43 6 0.63 2.90 6 0.43 3.03 6 0.41 3.45 6 0.69 3.42 6 0.64
SDMA (mmol/L) L-Arginine 2.74 6 0.98 3.33 6 1.22 3.20 6 0.84 4.34 6 1.98 4.40 6 1.51
PGE1 2.97 6 0.71 2.94 6 0.91 3.81 6 0.78 3.18 6 0.73 2.84 6 0.58
Control 2.98 6 0.60 2.55 6 0.44 2.85 6 0.56 3.06 6 0.56 3.11 6 0.53
L-arginine/ADMA ratio L-Arginine 26.5 6 4.4 65.0 6 28.3* 45.4 6 7.9* 51.7 6 11.4* 28.9 6 4.6
PGE1 34.5 6 5.6 32.0 6 5.7 30.9 6 7.5 30.7 6 6.9 33.1 6 5.9
Control 34.7 6 4.6 35.8 6 5.5 36.5 6 6.9 37.7 6 8.4 35.0 6 7.2
Data are given as mean 6 SEM. *p , 0.05 vs. baseline. SDMA 5 symmetric dimethylarginine; other abbreviations as in the text.
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lation in response to ischemia in the diseased leg and with
increased urinary NO metabolite excretion rates.
Improvement in walking distance. While recent placebo-
controlled studies have shown that intravenous PGE1 improves
claudication distances in PAOD patients (4), the finding that
infusion therapy with L-arginine improves the pain-free and
absolute walking distances is novel. Treadmill testing is the
method of choice to assess the patients’ walking distances. A
treadmill velocity of ;3 km/h (;2 mph) and a slope of ;12%
have been recommended in national and international guide-
lines to ensure reproducibility and to limit variability of the
results obtained (14–16). Treatment with L-arginine and with
PGE1 resulted in a significant increase of both the pain-free
and the absolute walking distances. The percent increase over
baseline was similar for both drugs during 3 weeks of active
treatment (pain-free walking distance: L-arginine, 1230 6
63%; PGE1, 1209 6 63%; absolute walking distance:
L-arginine, 1155 6 48%; PGE1, 1144 6 28%). It is important
to note that the walking distances assessed on a treadmill
under the conditions we used are to be multiplied by about
three to four to reflect the change of the patients’ community-
based walking ability (22).
Hemodynamic effects of L-arginine. The mechanism(s) be-
hind this therapeutic effect of L-arginine may be multifactorial.
In a previous study we found that a single intravenous infusion
of L-arginine increases femoral arterial blood flow in patients
with critical limb ischemia (13), suggesting peripheral arterio-
lar vasodilation. This was paralleled by increased urinary
excretion rates of nitrate and cGMP. We could recently
corroborate this finding by demonstrating improved nutritive
capillary muscular perfusion of the calves in PAOD patients
after a single intravenous infusion of 30 g of L-arginine, as
measured using 15O-water positron emission tomography (23).
Peripheral vasodilation is also achieved with PGE1 (13),
although a beneficial effect of intravenous PGE1 on nutritive
tissue perfusion has not yet been conclusively shown (24). The
major difference between both treatments is that L-arginine
restores endogenous NO formation rates, which are impaired
in atherosclerotic subjects (10), whereas PGE1 mimicks the
effects of prostacyclin.
Nitric oxide, but not prostacyclin, is the principal mediator
of flow-induced vasodilation of human peripheral conductance
arteries (25). Joannides et al. (25) reported that infusion of the
NO synthase inhibitor NG-monomethyl-L-arginine reduced
flow-induced brachial artery vasodilation during hyperemia as
well as the duration of the hyperemic response, but not the
peak increase in hyperemic blood flow in healthy humans. In
the present study we observed the opposite effects during
chronic intermittent intravenous L-arginine therapy. At base-
line, flow-induced femoral vasodilation was reduced in the
femoral artery of PAOD patients, as previously observed by
Cox et al. (26) and Nabel et al. (27) in atherosclerotic human
coronary arteries. Despite no significant change in peak hyper-
emic blood flow, the duration of hyperemia (AUC and t1/2 of
the hyperemic reaction) was markedly increased after 3 weeks
of L-arginine therapy, as was the flow-induced vasodilator
response. Neither PGE1 infusion nor exercise alone had a
significant effect on flow-induced vasodilation.
The increased flow-induced vasodilator response after
L-arginine therapy may indicate an improved ability of the
peripheral circulation to adapt to changes in nutritive demand
in skeletal muscle, which was also reflected by the higher
increase in postexercise ankle-arm blood pressure ratios in this
group as compared with PGE1 and controls. These results
suggest that the known beneficial effects of short-term
L-arginine infusion on endothelium-mediated vasodilation
(9,12) persist during longer-term intermittent infusion therapy
and result in improved peripheral blood flow at rest and during
exercise in patients with generalized atherosclerosis. A recent
study Rector et al. (28) reported that dietary supplementation
of patients with heart failure with L-arginine during 6 weeks
not only improved endothelium-mediated vasodilation, but
also increased exercise capacity and functional status of these
patients.
Improved peripheral blood flow also may be mirrored by
increased systolic ankle blood pressure. Ankle-arm blood
Figure 4. Urinary excretion rates of nitrate (a) and cGMP (b) in
patients with chronic intermittent claudication before, during and after
3 weeks of infusion therapy with L-arginine or PGE1, and in control
patients. Data are mean 6 SEM. *p , 0.05.
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pressure indices have been found to be an independent
measure of the mortality risk of PAOD patients (29). In the
present study, both L-arginine and PGE1 increased resting and
postexercise ankle-arm blood pressure indices. This effect was
greater in the L-arginine group; however, due to the small
group size the difference between both treatments did not
achieve statistical significance. Experimental data suggest that
improved collateral perfusion may be involved in the increased
peripheral blood supply after the infusion of L-arginine (30) as
well as PGE1 (31). Six weeks after the end of active treatment,
a slight tendency of walking distances and ankle-arm blood
pressure indices was noted to further increase in the L-arginine
group. No such tendency was observed in the PGE1 group.
These differences were not statistically significant and variabil-
ity was relatively high. However, it may be speculated that
other than direct hemodynamic effects of L-arginine may have
contributed to improved clinical outcome. Induction of collat-
eral growth by L-arginine has been demonstrated in rabbits
(32); it may also take place in atherosclerotic humans treated
with L-arginine. Collateral perfusion would still be present
after the end of intermittent intravenous L-arginine adminis-
tration. Whether such effects contribute to L-arginine’s effects
in human vascular disease remains to be established.
Limitations of the study. One limitation of our study is the
lack of a placebo group. We compared the effects of L-arginine
with those of PGE1, which is the current approved standard
therapy for patients with limb ischemia in our country, where
many patients with severe claudication are treated as inpa-
tients to receive a twice-daily infusion regimen of intravenous
PGE1. To eliminate any potential differences between both
groups due to incomplete absorption, L-arginine was also
administered as a twice-daily intravenous infusion regimen.
Prostaglandin E1 has been shown previously to induce superior
clinical benefit in patients with intermittent claudication as
compared with placebo. In a recently published study, intrave-
nous PGE1 improved the claudication distance of PAOD
patients significantly more than placebo (4). Moreover, PGE1
has been shown to exert a significant additive beneficial effect
during vascular training in patients with PAOD Fontaine stage
IIb (5). In the present study a third group of patients without
any vasoactive medication was studied as a control group. Both
hemodynamically active treatments had superior effects as
compared with vascular training alone, which caused only
insignificant increases in the pain-free and absolute walking
distances by 34 6 7% and 49 6 16%, respectively. These rates
of improvement are within the range of changes induced by
exercise programs reported previously by others (for reviews,
see references 16 and 33). Although all patients in the three
groups were instructed about vascular training with the help of
a formalized instruction sheet and training was supervised
once a week in each group, we cannot completely exclude the
possibility that patients in the L-arginine and PGE1 groups may
have adhered more closely to the training program, and that
better compliance may have contributed to better clinical
outcome in these groups.
L-Arginine administration and vascular NO production.
We have recently reported that NO formation rate is signifi-
cantly reduced in PAOD patients in a manner related to the
severity of the atherosclerotic disease (10). These data, which
were obtained using the urinary excretion rates of nitrate and
cGMP as noninvasive indices of systemic NO production,
corresponded well to the impaired endothelium-dependent
vasodilator response in patients with cardiovascular disease
previously reported by others (34,35). Moreover, we found that
accumulation of ADMA, an endogenous inhibitor of NO
synthesis (36), might be one causal factor for reduced NO
synthase activity (10). Increased ADMA concentrations result
in a reduced L-arginine/ADMA ratio, which may point to
reduced NO synthase substrate availability in atherosclerosis
and explain at least in part impaired NO elaboration in this
disease (37). The present study confirms the presence of
increased ADMA plasma concentrations in PAOD patients,
concomitantly with reduced L-arginine/ADMA ratio and low
urinary nitrate and cGMP excretion rates. L-Arginine infusion
restored this ratio to normal and increased the urinary excre-
tion rates of nitrate and cGMP.
Under conditions of impaired substrate availability, the
endothelial NO synthase may undergo structural disarrange-
ment, resulting in the conversion of this enzyme from an NO
synthase into a generator of superoxide anion in ischemic
rabbit hindlimb skeletal muscle (38,39). This effect is antago-
nized by excess L-arginine (38). Indeed, we have previously
demonstrated that chronic treatment with L-arginine prevents
vascular superoxide radical generation in cholesterol-fed rab-
bit aorta (8), an effect in which elevated levels of ADMA may
be involved (37). Decreased vascular oxidative stress may have
contributed to improved endothelial function in the L-arginine
group of the present study.
Other potential mechanisms of action of L-arginine. Other
mechanisms than hemodynamic mechanisms related to the
biological activity of NO may also have contributed to the
beneficial therapeutic effects of L-arginine in this study. Nitric
oxide is a known inhibitor of platelet activity (40). L-Arginine
also inhibits monocyte adhesion to the vascular endothelium
(41) and reduces vascular oxidative stress (8,42). Moreover,
L-arginine has been reported to exert analgesic effects (43),
whereas PGE1 itself induced pain and an inflammatory reac-
tion at the site of the infusion in one-third of our patients. No
such effects were observed for L-arginine, except for one case
of a mild allergic skin reaction. L-Arginine has previously been
reported to cause allergic reactions (44), but in general the
tolerability of L-arginine has been reported to be good (45).
In conclusion, our present study provides evidence that
chronic intermittent infusion therapy with L-arginine restores
systemic endogenous NO formation and concomitantly im-
proves the clinical symptoms of patients suffering from severe
intermittent claudication due to atherosclerotic peripheral
arterial disease. Restoration of endogenous NO production by
L-arginine may therefore be a novel approach in the therapy of
atherosclerotic vascular disease.
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